Pasithea shares fall 14.97% after-hours amid $60M public offering concerns over dilution.

Pasithea Therapeutics (KTTA) fell 14.97% in after-hours trading, driven by the announcement of a $60 million public offering priced at $0.75 per share, which triggered concerns over share dilution and pressured the stock. Despite recent positive developments—including a $1 million ALS grant, strong safety data for PAS-004, and insider purchases by directors and CEO Tiago Marques—the public offering, led by healthcare-focused investors and closing on December 1, overshadowed these catalysts. The offering, which included 80 million shares, raised approximately $60 million but signaled potential dilution risks, contributing to the sharp after-hours decline. Institutional buying by hedge funds and bullish insider activity contrasted with the negative market reaction, highlighting the stock’s volatility amid conflicting signals.